Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV venetoclax + rituximab in relapsed CLL (Poland)
2025-524795-35-00Phase 4Authorised
- Sponsor
- Medical University of Lublin
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of venetoclax and rituximab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Medical University of Lublin. Primary endpoint: Primary: Undetectable minimal residual disease rate. Planned start Jun 2026; status: authorised.
02
Drugs
venetoclaxrituximab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2025-524795-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524795-35-00.